Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Nasopharyngeal Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Head and Neck Cancer (561
)
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (291
)
Salivary Gland Cancer (57
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
Head and Neck Cancer (561
)
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (291
)
Salivary Gland Cancer (57
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
›
Associations
(59)
News
Trials
Search handles
@AnujkumarTvm
@CJTsaiMDPhD
@JoeChaoMD
@VivekSubbiah
@ryanhuey
Search handles
@AnujkumarTvm
@CJTsaiMDPhD
@JoeChaoMD
@VivekSubbiah
@ryanhuey
Filter by
Latest
9ms
Editorial: "Epstein–Barr Virus DNA Screening in Asymptomatic People without Known Nasopharyngeal Cancer," by @EIzumchenko and @eevokes. https://t.co/9hutbgzZel #cfDNA #NPC #Oncology @UChicagoHemOnc @UChicagoMed https://t.co/eKtN1fNmIp (@NEJMEvidence)
9 months ago
9ms
☢️👃Upper-neck irradiation 🆚standard whole-neck irradiation in nasopharyngeal carcinoma Systematic #review and #meta-analysis by multiple centers researchers 🔗https://t.co/qYwyTQ9yJ5 #radonc #hncsm @StAr_MCM74 (@TumoriJ)
9 months ago
Retrospective data • Review
10ms
Yes Sir. In unresectable recurrent nasopharyngeal cancers, results from this study are encouraging, showing an absolute 20 % improvement in 3 year OS Some caveats, for example late toxicities, may have been lower in the control arm if they used the 1.8 to 2 Gy/# rather than 2.2. (@AnujkumarTvm)
10 months ago
10ms
In this editorial, @EIzumchenko and @eevokes review the follow-up study by Chan et al. evaluating plasma Epstein–Barr virus (EBV) DNA and risk of future nasopharyngeal cancer (NPC). Prospects and limitations of EBV screening in people with no identifiable #NPC are discussed. (@NEJMEvidence)
10 months ago
Review
10ms
Hi Michael, our group has also looked at this issue in those with nasopharyngeal cancer, @TC30382220 @little_blackbk https://t.co/4NX3KZQB2F (@yysoon01)
10 months ago
10ms
Nasopharynx cancer experts/colleagues - what's your concurrent CRT dose/fraction after induction chemo? Please also explain your rationale. @DrMLChua @HenningWillers @henson_md @DrNikhilJoshiMD @cd_fuller @DanielMaMD @PBlanchardMD @henson_md @ChristinaChapMD @DavidSherMD (@CJTsaiMDPhD)
10 months ago
10ms
Check out Dr. Nabil Saba @DrNabilSaba @WinshipAtEmory discussing #ASCO23 Immunotherapy Trials for Nasopharyngeal Cancers #hncsm #OncEd #OncTwitter #VuMedi #PrecisionOncology #biomarkers #PrecisionMedicine #medonc #HeadandNeckCancers https://t.co/gqKYedGk7F (@Sameh_VuMedi)
10 months ago
IO biomarker
12ms
1/3 biopsy done Confirmed it to be nasopharyngeal carcinoma ( NPC) MRI showed intracranial extension PET showed no distant metastasis except intracranial extension Stage 4 NPC (@Satyayadav__)
12 months ago
Metastases • Biopsy
12ms
1/2 Malignancy highly likely causes could be ⏺️Nasopharyngeal carcinoma ⏺️Nasal NK/T cell lymphoma ⏺Burkitt lymphoma ⏺️Rhabdomyosarcoma Non-malignant causes ⏺️ Fungal ( Mucor/Fusarium/Aspergillus) ⏺️Nasopharyngeal Angiofibroma ⏺️ Hemangioma (@Satyayadav__)
12 months ago
almost3years
🚨 @asco #ASCO21 Plenary session 👉Summary slide from #JUPITER study for Systemic therapy of Recurrent/Metastatic Nasopharyngeal Cancer #ASCO21 👉 PFS benefit for Toripalimab ! Can this be extrapolated to other PD1/PDL1 drugs ? @OncoAlert (@VivekSubbiah)
almost 3 years ago
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Loqtorzi (toripalimab-tpzi)
almost3years
JUPITER-02: 1L recurrent/metastatic nasopharyngeal cancer, chemo w/ or w/o toripalimab (PD-1). PFS benefit. OS (secondary endpoint) not mature yet but curve here and HR 0.603. #ASCO21 (@ryanhuey)
almost 3 years ago
PD-1 (Programmed cell death 1)
|
Loqtorzi (toripalimab-tpzi)
3years
May do EBER if very high PD-L1 CPS, PD-L1 gene amp (yet to see), pathologist calling out lymphoepithelioma, or indolent disease course. Nice @OncJournal Italian cohort study of EBV+/- mGEA where prognosis very favorable even with chemo @FilippoPietran4 https://t.co/CDKa6IFBnA (@JoeChaoMD)
3 years ago
PD-L1 (Programmed death ligand 1)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login